Business Wire

VA-INTELSAT

23.5.2024 15:31:29 CEST | Business Wire | Press release

Share
Intelsat to Extend Life of Additional Satellites with Mission Extension Vehicles

Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), will deliver years of additional reliable broadband, video distribution and mobile satellite service to customers across three continents thanks to the success of Northrop Grumman’s innovative Mission Extension Vehicle (MEV) that will ultimately provide an expected additional nine years of life to the Intelsat 10-02 (IS-10-02) geosynchronous satellite.

Geosynchronous Earth orbit (GEO) satellites have an average lifespan of about 15-20 years before they start running low on fuel. Intelsat in 2020 became the first satellite operator to commit to deploying two of Northrop Grumman’s MEVs to extend the life of an otherwise healthy satellite. Both MEVs have been successful at their mission and have allowed IS-10-02 and Intelsat 901 (IS-901) to provide five years of service beyond the expected lifespan of the satellite. Under amendments to the original agreements with Northrop Grumman’s SpaceLogistics LLC, both MEVs will stay in space serving Intelsat satellites for several more years, allowing them to operate longer.

  • At the end of the current servicing period, MEV-1 will release the IS-901 satellite into the GEO graveyard and then provide service for another Intelsat satellite.
  • MEV-2 will remain docked to Intelsat’s current vehicle, IS-10-02, providing life-extension for several years – nearly doubling service from the original contract. The IS-10-02 satellite was manufactured by Airbus Defense & Space, was launched in June 2004 and entered service in August 2004. Capacity on the satellite is shared with Telenor Satellite. Today, MEV-2 is helping to extend the life of IS-10-02, so the satellite can continue providing high-quality media distribution and broadband services to our customers across Europe, the Middle East, Africa and South America. IS-10-02 is a key satellite in the Intelsat-Telenor Satellite video neighborhood, distributing more than 900 channels to nearly 18 million television households across Europe.

“As the largest satellite operator in geosynchronous orbit, Intelsat has always been committed to continuous reliable service, as well as leadership in furthering sustainable space operations,” said Jean-Luc Froeliger, SVP Space Systems at Intelsat. “Intelsat continues to pursue first-of-their-kind innovations to extend the life of its satellites in orbit, while also bringing the industry together to foster information sharing and collaboration across a challenging regulatory environment to achieve sustainable stewardship of the resource of space.”

“This extension is excellent news for our many clients across Europe and the Middle East who are served by THOR 10-02,” said Morten Tengs, CEO of Telenor Satellite. “We pride ourselves on the resilience of our service and, by extending the life of the satellite, we can ensure continuity and hassle-free operations for a number of years.”

MEV Background

In 2020, MEV-1 successfully docked with the IS-901 satellite, a high-performing satellite that was running low on fuel. That marked the first time that two commercial spacecraft docked and began mission-extension service in GEO. The in-space maneuver pointed IS-901 to targeted antennas on Earth and extended its life for another five years of its lifespan.

In 2021, the feat was repeated with a second MEV-2 docking with the IS-10-02 satellite. Unlike the first docking, which was performed in a graveyard orbit a few hundred kilometers above active satellites, this time the MEV-2 docked with IS-10-02 in its original orbital slot and avoided any interruption of services to customers, resulting in the first-ever in-orbit servicing of a live commercial satellite in GEO.

About Intelsat

Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.

Follow Us on Social Media:
X | LinkedIn | Instagram | YouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523619448/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye